Liensinine perchlorate

製品番号: HY-N5014 純度: 99.67%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 2385-63-9

容量	価格（税別）	在庫状況	数量
5 mg	$99	在庫あり	Estimated Time of Arrival: December 31
10 mg	$168	在庫あり	Estimated Time of Arrival: December 31
20 mg	$286	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 20 publication(s) in Google Scholar

Other Forms of Liensinine perchlorate:

Liensinine 在庫あり
Liensinine Diperchlorate 在庫あり

顧客検証

Cell Proliferation/Viability Assay

Flow Cytometry

Cell Imaging/Staining

RT-PCR

: Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]; The viability of HBE cells treated with different concentration of Liensinine (LIE) (10, 20, 40, 60, 80 μM) measured by CCK8 assay.

: Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]; Liensinine (LIE) (40 μM) treatment effectively suppressed autophagy by Western blot.

: Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]; Liensinine (LIE) (40 μM) improved mitochondrial damage induced by ARSK knockdown, as evidenced by the reductions in intracellular and mitochondrial ROS levels.

: Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]; SA-β-gal staining results demonstrated that Liensinine (LIE) (40 μM) treatment obviously decreased the percentage of positive cells.

: Liensinine perchlorate purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul 31:86:103793. [Abstract]; The expressions of IL-6, IL-8 and IL-1β were both relived in HBE cells by Liensinine (LIE) (40 μM).

JAK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

JAK1 JAK2 JAK3 Tyk2 JAK

Akt アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Akt Akt1 Akt2 Akt3

p38 MAPK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

VEGFR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

STAT アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

STAT3 STAT5 STAT6 STAT1

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

HIF-1α HIF

JNK アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

JNK1 JNK2 JNK3 JNK

PI3K アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明	Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke^[1]^[2]^[3]^[4]^[5].
IC₅₀ & Target	IC50: apoptosis^[1]
体外実験	Liensinine (5-80 μM; 24 h) perchlorate reduces the viability of SaOS-2, MG-63, 143B and U-2OS osteosarcoma cells in a dose-dependent manner, but has no effect on the viability of hFOB 1.19 normal osteoblasts^[1]. Liensinine (40-80 μM; 24 h) perchlorate inhibits the proliferation and colony-forming ability of SaOS-2 and 143B osteosarcoma cells, induces apoptosis, and causes G0/G1 cell cycle arrest in a dose-dependent manner^[1]. Liensinine (40-80 μM; 24 h) perchlorate increases intracellular ROS production in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner, but does not affect ROS levels in hFOB 1.19 normal osteoblasts^[1]. Liensinine (40-80 μM; 24 h) perchlorate disrupts the GSH/GSSG redox balance in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner by decreasing GSH levels, increasing GSSG levels, and elevating the GSSG/GSH ratio^[1]. Liensinine (40-80 μM; 24 h) perchlorate induces the loss of mitochondrial membrane potential in SaOS-2 and 143B osteosarcoma cells in a dose-dependent manner^[1]. Liensinine (40-80 μM; 24 h) perchlorate dose-dependently regulates the expression of apoptosis- and cell cycle-related proteins in SaOS-2 and 143B osteosarcoma cells in vitro, and inhibits the activation of the JAK2/STAT3 pathway, but exerts no effect on the aforementioned proteins in hFOB 1.19 normal osteoblasts^[1]. Liensinine (20 μM; 24 h) perchlorate enhances cell viability, reduces apoptosis and cytotoxicity, and inhibits autophagy in an in vitro oxygen-glucose deprivation/reoxygenation ischemia-reperfusion model^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Liensinine perchlorate 関連抗体
体内実験	Liensinine (20 mg/kg; i.p.; once daily; for 21 consecutive days) perchlorate significantly inhibits the growth of subcutaneous hepatocellular carcinoma (HCC) xenografts in male BALB/c nude mice, reduces tumor vascular density, and reshapes the tumor immune microenvironment into an anti-tumor phenotype^[5]. Liensinine (20 mg/kg; i.p.; once daily for 16 consecutive days) perchlorate significantly inhibits orthotopic HCC tumor progression in male C57BL/6 mice, induces tumor metabolic reprogramming, reduces tumor vascular density, regulates macrophage polarization, and downregulates PD-L1 expression^[5]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
分子式	C₃₇H₄₂N₂O₆.xHClO₄
CAS 番号	2385-63-9
Appearance	Solid
Color	White to off-white
SMILES	OC1=CC=C(C[C@H]2N(C)CCC3=C2C=C(OC)C(OC)=C3)C=C1OC4=CC5=C(C=C4OC)CCN(C)[C@@H]5CC6=CC=C(O)C=C6.[x HClO4]
Structure Classification	Alkaloids Isoquinoline Alkaloids Phenols Polyphenols
Initial Source	Plants other families
輸送条件	Room temperature in continental US; may vary elsewhere.
保管条件	4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶剤 & 溶解度	体外: DMSO : 100 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Molarity Calculator Dilution Calculator Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Mass = Concentration × Volume × Molecular Weight * Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final) 一般には略語で表示されます：C₁V₁ = C₂V₂ 濃度 _（開始） C1 × 体積 _（開始） V1 = 濃度 _（終了） C2 × 体積 _（終了） V2 体内: Select the appropriate dissolution method based on your experimental animal and administration route. For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents: To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution. Protocol 1 Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline Solubility: ≥ 2.08 mg/mL; Clear solution This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL. Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution. Protocol 2 Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline) Solubility: ≥ 2.08 mg/mL; Clear solution This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear. Protocol 3 Add each solvent one by one: 10% DMSO 90% Corn Oil Solubility: ≥ 2.08 mg/mL; Clear solution This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully. Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly. In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Dosage mg/kg Animal weight (per animal) g Dosing volume (per animal) μL Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments. Please enter your animal formula composition: % DMSO + % + % Tween-80 + % Saline Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak. The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE). Calculation results: Working solution concentration: mg/mL Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL). In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE). Tel: 609-228-6898 E-mail: [email protected] Technical Support: [email protected] Method for preparing in vivo working solution for animal experiments:* Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline. Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution If the continuous dosing period exceeds half a month, please choose this protocol carefully. Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション	純度: 99.67% Select Batch: データシート (278 KB) SDS (252 KB) COA (251 KB) LCMS (85 KB) 取扱説明書 (2659 KB)
参考文献	[1]. Jia F, et al. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway. Oxid Med Cell Longev. 2022;2022:8245614. Published 2022 Jan 25. [Content Brief] [2]. Zhang W, et al. Liensinine pretreatment reduces inflammation, oxidative stress, apoptosis, and autophagy to alleviate sepsis acute kidney injury. Int Immunopharmacol. 2023;122:110563. [Content Brief] [3]. Qiao W, et al. Liensinine ameliorates ischemia-reperfusion-induced brain injury by inhibiting autophagy via PI3K/AKT signaling. Funct Integr Genomics. 2023;23(2):140. Published 2023 Apr 28. [Content Brief] [4]. Wu MC, et al. Liensinine and neferine exert neuroprotective effects via the autophagy pathway in transgenic Caenorhabditis elegans. BMC Complement Med Ther. 2023;23(1):386. Published 2023 Oct 27. [Content Brief] [5]. Liu J, et al. Liensinine reshapes the immune microenvironment and enhances immunotherapy by reprogramming metabolism through the AMPK-HIF-1α axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44(1):208. Published 2025 Jul 15. [Content Brief]